Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aticaprant (JNJ-67953964) in Major Depressive Disorder
NCT03559192Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jul 2018
- Primary completion
- May 2020
- Modality
- Small Molecules
- Countries
- 6
01
Overview
A Phase 2 trial of aticaprant in major depressive disorder (MDD), sponsored by Janssen Pharmaceutical. Started Jul 2018; status: completed.
02
Drugs
aticaprant
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT03559192.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03559192.